Patients with rheumatoid arthritis (RA) now have a first-of-its-kind therapeutic option that is safe, convenient, and effective. The FDA recently approved adalimumab (Humira, Abbott Laboratories) for reducing the signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active RA who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). The approval of adalimumab comes just nine months after regulatory submission. Adalimumab will be available in pharmacies by mid-January.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.